Pharmathen is delighted to announce that it has been shortlisted as one of the finalists for the “Global Generics & Biosimilars Awards 2019”. These awards aim at rewarding ‘best practice’ in the two industries, while, at the same time, encouraging improvements in every aspect of the way business is conducted.
The new plant is part of the company’s total investment plan of over €250 million for the next five years, which will lead to the creation of at least 300 new jobs. Sapes – Rodopi, the 6th of September, 2019. Pharmathen’s new Long-Acting Injectables Unit was officially launched today by the Minister of Development and Investments, Mr. Adonis Georgiadis; during a ceremony attended by representatives of the central and local government, the scientific and business community, and the Media.
For yet another year, Pharmathen participates in CPhI Worldwide exhibition 2019 in Frankfurt @Stand No 80C72.
For yet another year, we received the “Diamonds of the Greek Economy” distinction at the business...
Another great distinction for our company!
We are proud of our legal team’s distinction to be among the “Legal 500 2019 General Counsel Powerlist: Greece & Cyprus” that were honored in a reception that took place in Athens on 16 May 2019.
Pharmathen proceeded to new investments and acquired an additional 27-acres land in the Industrial Park of Sapes in order to expand its innovative business.
Pharmathen’s press event for its 50-years milestone
Coming together from all around the globe, we celebrated with our people 50 years of operation...
For yet another year, Pharmathen has been distinguished at the “2018 EU Industrial R&D Investment Scoreboard” and is ranked first among Greek companies based on R&D spending, by investing 33% of its turnover. With annual R&D spending of 49.9 million euros in the 2017-2018 period, Pharmathen ranked 396th on this year’s list of 1,000 companies in the EU with the highest R&D expenditure.